Bavachalcone
Based on 2 publication(s) in Google Scholar
Bavachalcone is a potent inducer of apoptosis. Bavachalcone exerts anticancer activity by promoting autophagy and apoptosis in HepG2 cells. Bavachalcone acts as an anti-neuroinflammatory and antidepressant through the NF-κB pathway. Bavachalcone inhibits osteoclasts by interfering with ERK and Akt signaling pathways and the expression of c-Fos and NFATc1. Bavachalcone exhibits a significant inhibitory effect on baculovirus-expressed BACE-1 in vitro.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.90%
- CAS No.: 28448-85-3
- Formule: C20H20O4
- Masse moléculaire:324.37
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Bavachalcone
MoreVoir tous les produits spécifiques à Isoform Antibiotic
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 9
|
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| HUVEC | IC50 |
39.73 μM
Compound: 1a
|
Toxicity against HUVEC incubated for 48 hrs by MTT assay
Toxicity against HUVEC incubated for 48 hrs by MTT assay
|
[PMID: 25590864] |
| K562 | IC50 |
>10 μM
Compound: 9
|
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
Cytotoxicity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 25710081] |
| K562 | IC50 |
2.77 μM
Compound: 1a
|
Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay
Antitumor activity against human K562 cells incubated for 48 hrs by MTT assay
|
[PMID: 25590864] |
Bavachalcone (5 μg/mL; 1-48 h) inhibits osteoclasts by interfering with ERK and Akt signaling pathways and the expression of c-Fos and NFATc1[1].
.
Bavachalcone (0-100 μg/mL; 24h) is toxic to HepG2 cells with IC50 of 20 μg/mL[3].
Bavachalcone (20 μg/mL; 24 h) induces apoptosis in HepG2[3].
Bavachalcone (0-20 μg/mL; 24 h) induces cell cycle arrest in HepG2 cells[3].
Bavachalcone (0-20 μg/mL; 24 h) induces autophagy through Akt-mTOR signaling pathway[3].
Bavachalcone (5-10 μM; 2 h) inhibits the activation of NF-κB pathway in LPS (HY-D1056)-induced BV2 cells, upregulated the expression of A20 and TAX1BP1, and enhanced their interaction[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RANKL treated bone marrow-derived macrophages
-
Concentration:5 μg/mL
-
Incubation Time:0, 12, 24 and 48 h;
1 h -
Result:Reduced the levels of c-Fos and NFATc1.
Reduced the phosphorylation levels of ERK and Akt.
-
Cell Line:HepG2 cell
-
Concentration:20 μg/mL
-
Incubation Time:24 h
-
Result:Significantly increased the levels of caspase-3.
-
Cell Line:HepG2 cell
-
Concentration:0, 5, 10 and 20 μg/mL
-
Incubation Time:24 h
-
Result:Decreased the levels of early cell cycle regulatory proteins cdk4 and cdk2.
Increased the levels of p21 and p27.
Inhibited the phosphorylation and expression of both Akt and mTOR.
-
Cell Line:LPS (HY-D1056) treated BV2 cells
-
Concentration:5 μM and 10 μM
-
Incubation Time:2 h
-
Result:Significantly decreased the expression of TRAF6 and phosphorylation of P65 and IκBα.
Increased the expression of A20 and TAX1BP1
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS (HY-D1056) treated male C57BL/6 mice (8 weeks, 20 ± 2 g)
-
Dosage:30 mg/kg and 60 mg/kg
-
Administration:Intraperitoneal injection (i.p.); 4 days
-
Result:Attenuated LPS-induced depression-like behaviors in mice.
Inhibited LPS-induced activation of microglia in the brain of mice.
Inhibited LPS-induced NF-κB pathway activation and upregulated the expression of A20 and TAX1BP1 in the cortex of mice.
Weakened the production of TNF-α and IL-6 in the cortex of mice.
Chemical Information
-
CAS No. 28448-85-3
-
Appearance Solid
-
Masse moléculaire 324.37
-
Formule C20H20O4
-
Color Yellow to orange
-
SMILES
O=C(C1=CC(C/C=C(C)\C)=C(O)C=C1O)/C=C/C2=CC=C(O)C=C2
-
Synonyms
Broussochalcone B
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Chem Biol Interact
Bavachinin, a main compound of Psoraleae Fructus, facilitates GSDMD-mediated pyroptosis and causes hepatotoxicity in mice. [Abstract]2024 Jul 3:111133. PMID: 38969277 -
BMC Cancer
4'-O-Methylbroussochalcone B as a novel tubulin polymerization inhibitor suppressed the proliferation and migration of acute myeloid leukaemia cells. [Abstract]2021 Jan 22;21(1):91. PMID: 33482772
Solvant et solubilité
DMSO : ≥ 34 mg/mL (104.82 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Park CK, et al. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL. Biochem Pharmacol. 2008 Jun 1;75(11):2175-82. [Content Brief]
[2]. Choi YH, et al. In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia. Planta Med. 2008 Sep;74(11):1405-8. [Content Brief]
[3]. Song HS, et al. Bavachalcone from Cullen corylifolium induces apoptosis and autophagy in HepG2 cells. Phytomedicine. 2018 Feb 1;40:37-47. [Content Brief]
[4]. Wu X, et al. Upregulation of A20 and TAX1BP1 contributes to the anti-neuroinflammatory and antidepressant effects of bavachalcone. Int Immunopharmacol. 2023 Sep;122:110552. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0829 mL | 15.4145 mL | 30.8290 mL | 77.0725 mL |
| 5 mM | 0.6166 mL | 3.0829 mL | 6.1658 mL | 15.4145 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0829 mL | 7.7072 mL | |
| 15 mM | 0.2055 mL | 1.0276 mL | 2.0553 mL | 5.1382 mL | |
| 20 mM | 0.1541 mL | 0.7707 mL | 1.5414 mL | 3.8536 mL | |
| 25 mM | 0.1233 mL | 0.6166 mL | 1.2332 mL | 3.0829 mL | |
| 30 mM | 0.1028 mL | 0.5138 mL | 1.0276 mL | 2.5691 mL | |
| 40 mM | 0.0771 mL | 0.3854 mL | 0.7707 mL | 1.9268 mL | |
| 50 mM | 0.0617 mL | 0.3083 mL | 0.6166 mL | 1.5414 mL | |
| 60 mM | 0.0514 mL | 0.2569 mL | 0.5138 mL | 1.2845 mL | |
| 80 mM | 0.0385 mL | 0.1927 mL | 0.3854 mL | 0.9634 mL | |
| 100 mM | 0.0308 mL | 0.1541 mL | 0.3083 mL | 0.7707 mL |